Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria

The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization

(2021) Andreas Schwarting et al.   Rheumatology and Therapy

Clinical disease activity and flare in SLE: Current concepts and novel biomarkers

(2021) Aikaterini Thanou et al.   JOURNAL OF AUTOIMMUNITY

Current Status of the Evaluation and Management of Lupus Patients and Future Prospects

(2021) Sule Yavuz et al.   Frontiers in Medicine

Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review

(2021) Manuel Francisco Ugarte-Gil et al.   Lupus Science & Medicine

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

(2020) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach

(2020) John G Hanly et al.   ANNALS OF THE RHEUMATIC DISEASES

US, EU, and Japanese Regulatory Guidelines for Development of Drugs for Treatment of Alzheimer’s Disease: Implications for Global Drug Development

(2020) Anne Vinther Morant et al.   CTS-Clinical and Translational Science

Current and future outlook on disease modification and defining low disease activity in systemic sclerosis

(2020) Vivek Nagaraja et al.   Arthritis & Rheumatology

2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis

(2020) Antonis Fanouriakis et al.   ANNALS OF THE RHEUMATIC DISEASES

Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers

(2020) Simon A. Carter et al.   Clinical Journal of the American Society of Nephrology

Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis

(2020) Irene B Murimi-Worstell et al.   BMJ Open

Early disease and low baseline damage predict response to belimumab in patients with systemic lupus erythematosus

(2020) Mariele Gatto et al.   Arthritis & Rheumatology

Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis

(2019) Murray B Urowitz et al.   ANNALS OF THE RHEUMATIC DISEASES

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

(2019) Antonis Fanouriakis et al.   ANNALS OF THE RHEUMATIC DISEASES

The majority of Swedish systemic lupus erythematosus patients are still affected by irreversible organ impairment: factors related to damage accrual in two regional cohorts

(2019) M Frodlund et al.   LUPUS

Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency

(2019) Andrew S. Levey et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Clinical aspects and risk factors of lupus nephritis: a retrospective study of 156 adult patients

(2019) Fang Yuan et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort

(2019) Beatriz Tejera Segura et al.   RHEUMATOLOGY

Economic evaluation of damage accrual in an international SLE inception cohort using a multi‐state model approach

(2019) Megan R.W. Barber et al.   ARTHRITIS CARE & RESEARCH

SLE Plasma Profiling Identifies Unique Signatures of Lupus Nephritis and Discoid Lupus

(2019) Michael A. Smith et al.   Scientific Reports

Trial of Anifrolumab in Active Systemic Lupus Erythematosus

(2019) Eric F. Morand et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort

(2018) Michelle Petri et al.   Arthritis & Rheumatology

Factors affecting quality of life in patients with systemic lupus erythematosus: important considerations and potential interventions

(2018) Claudia Elera-Fitzcarrald et al.   Expert Review of Clinical Immunology

Measuring Disease Activity and Damage with Validated Metrics: A Systematic Review on Mortality and Damage in Systemic Lupus Erythematosus

(2018) Stephanie O. Keeling et al.   JOURNAL OF RHEUMATOLOGY

Diagnosis and Management of Rheumatoid Arthritis

(2018) Daniel Aletaha et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years

(2017) M Taraborelli et al.   LUPUS

Biomarkers of lupus nephritis histology and flare: deciphering the relevant amidst the noise

(2017) Daniel J Birmingham et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Defining Low Disease Activity in Systemic Lupus Erythematosus

(2017) Ari Polachek et al.   ARTHRITIS CARE & RESEARCH

Disease modification and Neuroprotection in neurodegenerative disorders

(2017) Jeffrey Cummings   Translational Neurodegeneration

A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)

(2016) Ronald van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Disease Modification in Emphysema Related to Alpha-1 Antitrypsin Deficiency

(2016) Joanna Chorostowska-Wynimko   COPD-Journal of Chronic Obstructive Pulmonary Disease

Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis

(2016) Maria G. Tektonidou et al.   Arthritis & Rheumatology

Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)

(2015) Kate Franklyn et al.   ANNALS OF THE RHEUMATIC DISEASES

Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis

(2015) Chandra Mohan et al.   Nature Reviews Nephrology

A history of the term “DMARD”

(2015) Jonas Kure Buer   INFLAMMOPHARMACOLOGY

GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration

(2014) Andrew S. Levey et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

(2014) Ian N Bruce et al.   ANNALS OF THE RHEUMATIC DISEASES

Predictors of organ damage in systemic lupus erythematosus: The Hopkins Lupus Cohort

(2012) Michelle Petri et al.   ARTHRITIS AND RHEUMATISM

Taming lupus—a new understanding of pathogenesis is leading to clinical advances

(2012) Zheng Liu et al.   NATURE MEDICINE

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort

(2011) R. Lopez et al.   RHEUMATOLOGY

Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort

(2011) M. B. Urowitz et al.   ARTHRITIS CARE & RESEARCH

Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus

(2010) J. Nossent et al.   LUPUS

Defining disease-modifying therapies for PD-A road map for moving forward

(2010) C. Warren Olanow et al.   MOVEMENT DISORDERS

Defining and labeling disease-modifying treatments for Alzheimer's disease

(2009) Jeffrey L. Cummings   Alzheimers & Dementia

Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort

(2009) Guillermo J. Pons-Estel et al.   ARTHRITIS AND RHEUMATISM

Defining Disease Modification in Chronic Obstructive Pulmonary Disease

(2009) David M.G. Halpin et al.   COPD-Journal of Chronic Obstructive Pulmonary Disease

SLEDAI-2K for a 30-day window

(2009) Z. Touma et al.   LUPUS

Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years

(2009) S. A. Chambers et al.   RHEUMATOLOGY

Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2‐year prospective study

(2008) C. C. Mok et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY